PULMONX CORP (LUNG) Stock Price & Overview
NASDAQ:LUNG • US7458481014
Current stock price
The current stock price of LUNG is 1.44 USD. Today LUNG is up by 5.11%. In the past month the price decreased by -14.29%. In the past year, price decreased by -68.14%.
LUNG Key Statistics
- Market Cap
- 60.826M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.33
- Dividend Yield
- N/A
LUNG Stock Performance
LUNG Stock Chart
LUNG Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LUNG. When comparing the yearly performance of all stocks, LUNG is a bad performer in the overall market: 93.26% of all stocks are doing better.
LUNG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LUNG. LUNG has a bad profitability rating. Also its financial health evaluation is rather negative.
LUNG Earnings
On March 4, 2026 LUNG reported an EPS of -0.25 and a revenue of 22.60M. The company beat EPS expectations (37.47% surprise) and beat revenue expectations (1.96% surprise).
LUNG Forecast & Estimates
12 analysts have analysed LUNG and the average price target is 5.27 USD. This implies a price increase of 265.97% is expected in the next year compared to the current price of 1.44.
For the next year, analysts expect an EPS growth of 12.83% and a revenue growth 1.35% for LUNG
LUNG Groups
Sector & Classification
LUNG Financial Highlights
Over the last trailing twelve months LUNG reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.77% | ||
| ROE | -99.79% | ||
| Debt/Equity | 0.68 |
LUNG Ownership
LUNG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.66 | 174.288B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.91 | 160.047B | ||
| SYK | STRYKER CORP | 22.96 | 129.888B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.12 | 91.831B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.93 | 44.895B | ||
| IDXX | IDEXX LABORATORIES INC | 38.76 | 44.714B | ||
| BDX | BECTON DICKINSON AND CO | 11.39 | 43.913B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.29 | 33.391B | ||
| RMD | RESMED INC | 18.75 | 33.342B | ||
| DXCM | DEXCOM INC | 24.82 | 24.639B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.24 | 18.025B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 30.51 | 13.864B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LUNG
Company Profile
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 296 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Company Info
IPO: 2020-10-01
PULMONX CORP
700 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Glendon E. French
Employees: 296
Phone: 16509342600
PULMONX CORP / LUNG FAQ
What does LUNG do?
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 296 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Can you provide the latest stock price for PULMONX CORP?
The current stock price of LUNG is 1.44 USD. The price increased by 5.11% in the last trading session.
Does PULMONX CORP pay dividends?
LUNG does not pay a dividend.
What is the ChartMill technical and fundamental rating of LUNG stock?
LUNG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for PULMONX CORP?
PULMONX CORP (LUNG) has a market capitalization of 60.83M USD. This makes LUNG a Micro Cap stock.
What is the ownership structure of PULMONX CORP (LUNG)?
You can find the ownership structure of PULMONX CORP (LUNG) on the Ownership tab.